SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?


To: Kimberly Lee who wrote (1686)4/13/1999 2:09:00 PM
From: IPOhopper  Respond to of 108040
 
WLDI News: Tuesday April 13, 12:57 pm Eastern Time

Company Press Release

Worlds Inc. Names Telecom Exec as Board
Chairman

Former WinStar Communications Vice Chairman/Co-Founder
Chrust Joins Internet Technology Company

BOSTON--(BUSINESS WIRE)--April 13, 1999-- Worlds Inc. (OTC: WLDI - news), a leader in three
dimensional (3D) Internet technology and content, today announced that it had named Steven G. Chrust, a
long-time telecommunications executive and Wall Street analyst, as chairman.

The announcement, made by Worlds president Thomas Kidrin, signifies a major commitment on the part of Worlds
to expand its business through mass distribution of its proprietary 3D Internet technology via CD and broadband
channels.

''Steve's involvement brings to Worlds insight and high level business relationships developed over two decades in
the telecommunications industry,'' said Kidrin. ''We are now poised to rapidly deploy our 3D Internet technology in
new business and broadband applications initially focusing on the record industry and other broadcast distribution
channels, such as high speed Internet access via cable modem systems.''

Chrust, most recently co-founder and vice chairman of WinStar Communications Inc. (NASDAQ: WCII - news),
brings more than 25 years of experience in the telecommunications industry to his new position at Worlds. He is
also the former chairman of AMNEX, a provider of long distance of operator services, and former executive vice
president of Executone Information Services, Inc.

Chrust, 49, has also been the director of technology research at Sanford C. Bernstein & Co., where he was named
one of the top telecommunications analysts for more than a decade by Institutional Investor and ranked number one
in the sector for five consecutive years.

Worlds Inc., founded in 1994, is a pioneer in the development of three dimensional Internet technology and the
creation of cutting edge 3D Internet virtual worlds for the recording, multi-media and entertainment industries.
Worlds provides imbedded software and content on compact discs (CDs), allowing the personal computer (PC)
user access to spatial environments by employing avatars (alter ego animated characters) for self representation on
the Internet.

''The Worlds 3D technology has enormous potential,'' Chrust said. ''I've spent a significant amount of time
evaluating the market and Worlds' position. I believe, the company is also perfectly positioned for a broadband
rollout over the next 12-24 months.''

Kidrin added, ''Steve spent five years at WinStar helping the company through its high growth, startup stages,
leading corporate development, strategic and capital planning and acquisitions. His experience in those areas,
coupled with our own expertise and technology, will provide us with the leadership we need for our next phase of
development.''

Chrust was also chairman of the Association for Local Telecommunications Services (ALTS), the national
organization representing facilities-based competitive local exchange carriers. He is founder and chairman of SGC
Advisory Services, Inc., an advisory and money-management service firm specializing in telecommunications and
technology.

Michael J. Scharf, currently chairman of Worlds, will remain on the Company's board of directors.

Forward-looking Statements: The information herein contains forward-looking statements that involve risks and
uncertainties. A number of factors could cause actual results, performance, and achievements of the company, or
industry results, to be materially different from any future results, performances or achievements expressed or
implied by such forward-looking statements. These factors include, but are not limited to, the competitive
environment, inflation, changes in the cost of goods and services, economic conditions in general and in the
Company's business, demographic changes, changes in the availability of and terms of financing to fund the
anticipated growth of the Company's business, the ability to attract and retain qualified personnel, changes in the
Company's capital plans, and other factors referenced herein and in the Company's filings with the SEC. In
addition, such forward-looking statements are necessarily dependent upon assumptions, estimates and dates that
may be incorrect or imprecise and involve known and unknown risks, uncertainties and other factors. Accordingly,
any forward-looking statements included herein do not purport to be predictions of future events of circumstances
and may not be realized. Forward-looking statements can be identified, by, among other things, the use of
forward-looking terminology such as ''believes,'' ''expects,'' ''may,'' ''will,'' ''should,'' ''seeks,'' ''anticipates,''
''intends'' or the negative of any thereof, or other variations thereon or comparable terminology, or by discussions
of strategy or intentions. Given these uncertainties, prospective investors are cautioned not to place undue reliance
on such forward-looking statements. The Company disclaims any obligation to update any such factors or to
announce publicly the results of any revisions to any of the forward-looking statements contained herein to reflect
future events or developments.



To: Kimberly Lee who wrote (1686)4/13/1999 2:22:00 PM
From: lightfoot  Read Replies (1) | Respond to of 108040
 
SHAL breaking resistance here, did you revise your target?



To: Kimberly Lee who wrote (1686)4/13/1999 2:25:00 PM
From: lightfoot  Respond to of 108040
 
DBOT might be one to watch for some impact from today's news!
I noticed an insider has filed to sell some shares in May already, he must be expecting some good things. Not much volume yet, and their earnings report on Yahoo shows breakeven. Surprised that a small biotech is actually not losing money!

(COMTEX) B: University of Pittsburgh Reports Exciting Preclinical Res
B: University of Pittsburgh Reports Exciting Preclinical Results With Demegen's
Peptide to the American Association for Cancer Research

PITTSBURGH (April 13) BW HEALTHWIRE -April 13, 1999--Demegen, Inc. (OTC
BB:DBOT) announced today that the University of Pittsburgh Cancer
Institute (UPCI) is presenting results of preclinical studies using the
Company's patented D2A21 peptide at this afternoon's annual meeting of
the American Association for Cancer Research in Philadelphia, Pa. The
report highlighted the new agent's promise against both aggressive and
slow-growing prostate cancer types.

Demegen's D2A21 peptide is a laboratory-synthesized small compound that
destroys a cancer cell by attaching to its surface and disrupting its
outer membrane. At therapeutic doses, D2A21 is designed to target and
lyse (eliminate) cancer cells, sparing the normal healthy cells and
tissues.

Results of UPCI preclinical studies show the D2A21 compound was
effective using several routes of administration, including
intravenous, subcutaneous, and oral. Treatment with D2A21 did not cause
any significant toxicities, according to the researchers who are now
conducting additional preclinical studies in preparation for testing
Demegen's compound in cancer patients.

"This agent represents a totally new way to attack cancer," said Robert
Getzenberg, Ph.D., principal investigator and assistant professor of
pathology, pharmacology, medicine, and surgery who co-directs UPCI's
Prostate and Urologic Cancer Center. "We're particularly encouraged
that this agent is effective against metastatic prostate cancer, which
is notoriously difficult to treat."

In the preclinical experiments conducted at UPCI, investigators used
Demegen's D2A21 to treat established aggressive prostate cancers in
rats. The researchers found that D2A21 inhibited tumor growth by as
much as 60 percent as compared to untreated animals.

In another experiment, researchers injected a group of rats with
typically lethal numbers of cancer cells and simultaneously treated
them with D2A21. Results showed that 75 percent of animals receiving
D2A21 survived versus only 25 percent of animals that did not receive
the peptide treatment. D2A21 was also able to reduce lung metastases by
90 percent.

Commenting on the report, Demegen CEO Richard Ekstrom stated, "We are
very pleased with the results of studies conducted thus far at the
University of Pittsburgh Cancer Institute. We look forward to continued
reports from the researchers as they proceed towards human clinical
trials."

Demegen, Inc., founded in 1992, is a research and development firm that
designs novel synthetic molecules for the treatment of cancer and
infectious diseases as well as disease resistant and nutritionally
enhanced commercial crops. The Company currently generates revenues
through licenses for two broad applications of its patented
technologies to Dow AgroSciences LLC.

Forward-looking statements in this release are made pursuant to the
"safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including but not limited
to, results of research and development, the U.S. Food and Drug
Administration and other regulatory agencies, increased competition,
product development and commercialization, and other risks detailed
from time to time in the Company's reports filed with the Securities
and Exchange Commission.